Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Ezetimibe and Insulin Resistance

Author(s): Djordje S. Popovic*, Stella Papachristou, Edita Stokic and Nikolaos Papanas

Volume 20, Issue 4, 2022

Published on: 01 March, 2022

Page: [315 - 317] Pages: 3

DOI: 10.2174/1570161120666220301140528

conference banner
« Previous Next »
[1]
Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. Int J Mol Sci 2020; 21: 4725.
[2]
Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: A retrospective matched-cohort study. JAMA Intern Med 2021; 181: 1562-74.
[3]
Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 2010; 15: 167-74.
[4]
Toth PP, Catapano AL, Farnier M, et al. Effect on fasting serum glucose levels of adding ezetimibe to statins in patients with nondiabetic hypercholesterolemia. Am J Cardiol 2016; 118: 1812-20.
[5]
Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial. Diabetologia 2014; 57: 878-90.
[6]
Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: More than cholesterol lowering? Curr Med Res Opin 2010; 26: 2517-20.
[7]
Katsiki N, Mikhailidis DP. Statins and diabetes mellitus progression: A fly in the ointment? Nat Rev Endocrinol 2021; 18: 137-8. Epub ahead of print
[http://dx.doi.org/10.1038/s41574-021-00612-z]
[8]
Hiramitsu S, Miyagishima K, Ishii J, et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60: 395-400.
[9]
Ohbu-Murayama K, Adachi H, Hirai Y, et al. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig 2015; 6: 325-33.
[10]
Adachi H, Nakano H, Yamamoto K, et al. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia. Lipids Health Dis 2015; 14: 1.
[11]
Tamaki N, Ueno H, Morinaga Y, Shiiya T, Nakazato M. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012; 19: 532-8.
[12]
Nakamura A, Sato K, Kanazawa M, et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels 2019; 34: 916-25.
[13]
Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: A randomised controlled study. Eur J Clin Invest 2012; 42: 1287-94.
[14]
Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
[15]
Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100: 46-52.
[16]
Ichimori S, Shimoda S, Goto R, et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J Diabetes Investig 2012; 3: 179-84.
[17]
González-Ortiz M, Martínez-Abundis E, Kam-Ramos AM, Hernández-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006; 20: 143-6.
[18]
Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137: 1571-82.

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy